<DOC>
	<DOCNO>NCT01233895</DOCNO>
	<brief_summary>Primary Objectives : Study Part 1 : Determine select dose AVE1642 administer every 3 week base pharmacokinetic ( PK ) ( Clearance AVE1642 ) , pharmacodynamic ( PD ) ( insulin-like growth factor 1 [ IGF-1 ] serum level ) parameter , eventual dose limit toxicity ( DLTs ) patient recurrent , refractory multiple myeloma ( MM ) . Study Part 2 : Assess safety combination select dose AVE1642 recommend dose Velcade® . Secondary Objectives : Study Part 1 : - To assess safety profile : type , incidence intensity drug relate adverse event ( AEs ) - To assess biological activity AVE1642 ( saturation receptor down-regulation ) malignant plasma cell peripheral blood mononuclear cell ( PBMC ) granulocytes - To assess biological activity AVE1642 signalization pathway IGF-1 system ( phosphorylated akt [ pAkt ] , phosphorylated erk [ pErk ] ) malignant plasma cell technically possible - To define PK profile AVE1642 , PD effect serum IGF 1 , GF 2 IGFBP-3 - To assess clinical efficacy ( complete response [ CR ] , partial response [ PR ] , minimal response [ MR ] stabilization ) base European group Blood Marrow Transplantation ( EBMT ) criterion , possible - To assess potential immunogenicity detection human antihumanized antibody ( HAHA ) anti-AVE1642 Study Part 2 : - To detect PK PD interaction AVE1642 Velcade® - To assess clinical efficacy ( CR , PR , MR , change [ NC ] ) accord EBMT criterion appropriate - To assess biological activity AVE1642 combination Velcade® malignant plasma cell collect bone marrow aspirate : saturation down-regulation insulin-like growth factor 1 receptor ( IGF-1R ) activity signalization pathway IGF-1 system ( pAkt , pErk ) feasible - To detect immunogenicity reaction ( HAHA ) - To characterize PK PD profile low dose ( 0.5 mg/kg ) AVE1642 expect non biologically active</brief_summary>
	<brief_title>Study AVE1642 Anti-IGF1R Monoclonal Antibody Patients With Advanced Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Multiple myeloma confirm bone marrow aspirate biopsy Patient relapse and/or refractory multiple myeloma least 1 standard therapy , demonstrate disease progression Previous exposure Velcade allow , provide DLTs Grade 3 observe previous treatment ( Part 2 study ) Prior therapy IGF1 system target compound History allogenic stem cell transplantation case concomitant immunosuppressive therapy within 6 month study entry . Patients undergone autologous stem cell transplantation ( ) may include study History organ transplant patient receive long term systemic immunosuppressive therapy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>